Sort
30,917 grants matching “tumor microenvironment”
Nanotechnology Platforms for the Prevention and Personalized Therapy of Pancreati
$553,162Craig D Logsdon · University Of Texas Hlth Sci Ctr Houston · U54 · FY2013 · CA
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
$553,091Xiaoguang Margaret Liu · Ohio State University · R01 · FY2024 · CA
Lactate production by tumor associated macrophages promotes tumorigenesis
$553,078Lev Becker · University Of Chicago · R01 · FY2023 · CA
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
$553,064Andre Elias Nel · University Of California Los Angeles · R01 · FY2021 · CA
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
$553,064Andre Elias Nel · University Of California Los Angeles · R01 · FY2020 · CA
Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment
$552,945Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors
$552,945Randolph J. Noelle · Dartmouth College · R01 · FY2019 · CA
A20 and Tumor Immune Responses
$552,905Averil I Ma · University Of California, San Francisco · R01 · FY2025 · CA
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial
$552,880Lei Zheng · Johns Hopkins University · R01 · FY2023 · CA
A20 and Tumor Immune Responses
$552,874Averil I Ma · University Of California, San Francisco · R01 · FY2024 · CA
Tumor immune and glycan biomarkers for progressive prostate cancer
$552,871Jennifer D Wu · Northwestern University At Chicago · R01 · FY2022 · CA
Role of metalloproteinases in mammary gland remodeling
$552,836Zena Werb · University Of California, San Francisco · R01 · FY2010 · CA
Understanding Immunotype, a Novel Biomarker for Checkpoint Blockade Resistance
$552,595Margaret Kathleen Callahan · University Of Connecticut Sch Of Med/Dnt · R01 · FY2025 · CA
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome
$552,594Lajos Pusztai · Yale University · R01 · FY2017 · CA
Development of novel protein-based therapeutics for lung cancer
$552,581Eric Alejandro Sweet-Cordero · University Of California, San Francisco · R01 · FY2022 · CA
Collagen Sequence Variants in Racial Disparities of Breast Cancer
$552,568Peggi M Angel · Medical University Of South Carolina · R01 · FY2020 · CA
The Oncogene Activated Mitochondrial Unfolded Protein Response Regulates Senescence Biology
$552,538Jerry Edward Chipuk · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer
$552,535Deborah W Knapp · Purdue University · U01 · FY2023 · CA
Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer
$552,526Kenneth P Olive · Columbia University Health Sciences · R01 · FY2024 · CA
Study interactions between lung microbiota and immune cells in NSCLC
$552,519Chen Zhao · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Mechanisms of Murine Turmor Eradication by Immunotherapy
$552,495Philip D Greenberg · University Of Washington · R01 · FY2013 · CA
Recombinant Interleukin-33 Immunotherapy for Pancreatic Cancer
$552,488Vinod P Balachandran · Sloan-Kettering Inst Can Research · P50 · FY2023 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
$552,383Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Targeting MTOR signaling in pancreatic cancer
$552,350Brian C Lewis · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · CA
Zebrafish core
$552,298Christine Kettenhofen · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA